NOORIK BIOPHARMACEUTICALS
Noorik Biopharmaceuticals is a privately owned drug development company based in Basel, Switzerland. Their focus is to address an unmet medical need at the crossroads of drug re-profiling and nephrology.
NOORIK BIOPHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2008-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.noorik.com
Status:
Active
Contact:
+41 76 398 7007
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Google Universal Analytics Apache Global Site Tag Euro Google Apps For Business
Similar Organizations
AlloCyte Pharmaceuticals AG
AlloCyte Pharmaceuticals AG (AlloCyte) is a privately held Swiss company founded in November 2011.
AOP Orphan Pharmaceuticals
AOP Orphan Pharmaceuticals engages in developing, marketing, and distributing medicines for orphan indications and complex diseases.
Huxley Pharmaceuticals
Huxley Pharmaceuticals is private life sciences company founded and managed by Aceras BioMedical, LLC.
InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company.
Mimetogen Pharmaceuticals
Mimetogen Pharmaceuticals is a clinical-stage ophthalmology drug development company.
Proreo Pharma Innovation
Proreo Pharma is a privately owned specialty pharmaceutical company based in switzerland.
Official Site Inspections
http://www.noorik.com Semrush global rank: 5.24 M Semrush visits lastest month: 1.56 K
- Host name: kud25.dns-net.ch
- IP address: 195.160.190.155
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Noorik Biopharmaceuticals"
Noorik Biopharmaceuticals - Home
Biopharmaceutical company developing ambrisentan, an endothelin receptor antagonist for the treatment of vascular diseases, including COVID-19 pneumonia and Portal Hypertension …See details»
Noorik Biopharmaceuticals - About Us
Noorik Biopharmaceuticals is a privately owned drug development company based in Basel, Switzerland. Noorik was built on the idea of addressing an unmet medical need and …See details»
Noorik Biopharmaceuticals AG - Swiss Biotech
Enzene, an integrated global CDMO offers services spanning discovery, development & commercial supply. Its patented fully-connected continuous manufacturing platform, …See details»
Organization | Noorik Biopharmaceuticals AG
Noorik Biopharmaceuticals AG Report issue For profit Phase 2 Founded: Basel Switzerland (2008)See details»
Noorik Biopharmaceuticals - Contact
Noorik is a clinical stage company developing ambrisentan as a therapy for Portal Hypertension. You can contact us here.See details»
Noorik Biopharmaceuticals - Crunchbase Company Profile
Noorik Biopharmaceuticals is a privately owned drug development company based in Basel, Switzerland. Their focus is to address an unmet medical need at the crossroads of drug re …See details»
Noorik Biopharmaceuticals - Media
Dec 13, 2021 · Noorik is a privately-owned, clinical-stage company based in Basel, Switzerland. Noorik is developing ambrisentan as a treatment for kidney, liver, and respiratory diseases. …See details»
Noorik Biopharmaceuticals AG - VentureRadar
Develops innovative drug solutions in nephrology by addressing unmet medical needs through drug re-profiling, based in Basel, Switzerland. "Noorik intends to develop N-001 for the …See details»
Noorik Biopharmaceuticals AG | LinkedIn
Noorik Biopharmaceuticals AG | 99 followers on LinkedIn. Biopharmaceutical company addressing unmet medical needs through drug repurposing.See details»
Noorik Biopharmaceuticals AG - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Noorik Biopharmaceuticals AG of Basel, BASEL-STADT. Get the latest business insights from Dun & …See details»
Noorik Biopharmaceuticals AG - Zefix
Noorik Biopharmaceuticals AG, in Basel, CHE-115.986.883, Aktiengesellschaft (SHAB Nr. 63 vom 02.04.2024, Publ. 1005998192).Statutenänderung: 20.06.2024. Zweck neu: Die Gesellschaft …See details»
Noorik Biopharmaceuticals - Craft
Noorik Biopharmaceuticals is a drug development company. It develops N-003, a proprietary formulation of ambrisentan suitable for the administration of alternative doses to patients with …See details»
Noorik Biopharmaceuticals - Ambrisentan
Noorik is a company focussed on research and development. As such, we are currently looking for Partners to co-develop micro-dose Ambrisentan, complete the technical and clinical …See details»
Noorik Biopharmaceuticals AG - startup.ch
Noorik Biopharmaceuticals, AG is a privately owned drug development company based in Switzerland. A virtual company, Noorik outsources all development work which allows for a …See details»
Noorik Biopharmaceuticals to develop treatment for severe Covid-19
Dec 15, 2021 · Noorik Biopharmaceuticals, a clinical-stage biopharmaceutical company repurposing micro-dose ambrisentan for the treatment of kidney, liver, and respiratory …See details»
Ambrisentan by Noorik Biopharmaceuticals for Hepatorenal …
Aug 28, 2024 · Noorik Biopharmaceuticals (Noorik) is a drug development company that discovers and develops drug candidates for the treatment of renal orphan diseases through …See details»
NOORIK BIOPHARMACEUTICALS ANNOUNCES THE SIGNING OF …
Dec 17, 2021 · Basel, Switzerland, December 13, 2021 – Noorik Biopharmaceuticals Ltd. (“Noorik”), a clinical-stage biopharmaceutical company repurposing micro-dose ambrisentan …See details»
Noorik Biopharmaceuticals - COVID
To determine if micro-dose Ambrisentan is safe and of clinical benefit in Severe COVID-19, Noorik has initiated a Phase II multi-center, randomised, placebo-controlled study in high-risk patients.See details»
Kinarus and Noorik awarded federal grants - Basel Area Business ...
Dec 13, 2021 · The Basel-based biopharmaceutical companies Kinarus and Noorik have been awarded federal grants for their clinical trials investigating drug candidates to combat Covid …See details»
Noorik Biopharmaceuticals - Portal Hypertension
Noorik is developing ambrisentan as a therapy for Portal Hypertension, a complication of cirrhosis leading to the onset of ascites, varices, variceal bleeding and hepatic encephalopathy.See details»